Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients.
Lee
M S
MS
Department of Internal Medicine, University of Ulsan, Seoul, Korea.
Kim
S M
SM
Kim
S B
SB
Lee
S K
SK
Park
J S
JS
Yang
W S
WS
D000328:Adult; D000368:Aged; D001779:Blood Coagulation Factors / Q000032:analysis*; D005167:Factor VII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011446:Prospective Studies; D014841:von Willebrand Factor / Q000032:analysis
D001779:Blood Coagulation Factors; D000960:Hypolipidemic Agents; D008055:Lipids; D014841:von Willebrand Factor; D005167:Factor VII; D005340:Fibrinogen; D015248:Gemfibrozil